Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Slightly Bearish -15

Novo Nordisk stock falls as US listing option enters debate

Market commentary Share buyback AI-generated analysis

📉 Novo Nordisk stock fell 2.13 percent to DKK 253.3 on September 23, 2026, amid debate over a potential direct New York Stock Exchange listing.

🗣️ CEO Mike Doustdar confirmed the company is open to considering a direct NYSE listing but emphasized it is not actively exploring the change or has started a formal process.

💰 The company repurchased 34.17 million B shares for DKK 9.63 billion by September 18, utilizing 64.2 percent of its DKK 15 billion buyback program.

📊 Novo Nordisk traded at DKK 253.3, which is 38.2 percent below its 52-week high of DKK 410.0 and 28.49 below the average buyback price.

🏦 Berenberg maintained a Neutral rating with a DKK 305 price target, implying approximately 20.4 percent upside from the September 23 market price.

📈 Novo Nordisk holds a market capitalization of DKK 1.13 trillion and operates in the Healthcare / Drug Manufacturers - General sector.

Bullish Signals
  • Novo Nordisk has executed significant share buybacks, purchasing 34.17 million shares for DKK 9.63 billion, representing 64.2 percent of its authorized DKK 15 billion program.
  • The average price paid during buybacks was DKK 281.79, indicating management's confidence that the stock is undervalued relative to the repurchase cost.
Risk Factors
  • Novo Nordisk shares declined 2.13 percent to DKK 253.3 on September 23, trading 38.2 percent below its 52-week high of DKK 410.0.
  • Analyst Berenberg maintains a Neutral rating with a price target of DKK 305, suggesting limited immediate upside from the current market price.
Full Analysis
Novo Nordisk shares declined by 2.13 percent to DKK 253.3 on September 23, 2026, following renewed speculation regarding a potential direct listing on the New York Stock Exchange. While CEO Mike Doustdar stated the company is open to considering such a move to replace its current American depositary receipt structure, he clarified that no formal process has been initiated and the company is not actively exploring the change at this time. The Danish pharmaceutical giant continues to execute its capital return program aggressively, having repurchased approximately 34.2 million B shares for DKK 9.63 billion by September 18. These buybacks accounted for 64.2 percent of the company's DKK 15 billion, 12-month authorization, with the average purchase price of DKK 281.79 standing significantly above the current market price of DKK 253.3. Analyst sentiment remains cautious regarding immediate upside, with Berenberg maintaining a Neutral rating and a DKK 305 price target as of September 22. Novo Nordisk's market capitalization stood at DKK 1.13 trillion on September 23, trading within a 52-week range between DKK 224.3 and its high of DKK 410.0. Despite the stock being 38.2 percent below its 52-week high, the company remains primarily listed in Copenhagen with US investors accessing shares via ADRs. The potential shift to a direct listing represents a strategic market-access decision rather than an immediate alteration to the underlying business operations or financial performance.